Austin v Roche Products (New Zealand) Ltd

Link copied
Case Copied 16 min read

FOR A COURT READY (FEE REQUIRED) VERSION PLEASE FOLLOW THIS LINK

IN THE SUPREME COURT OF NEW ZEALAND

I TE KŌTI MANA NUI

 SC 5/2020
 [2021] NZSC 30
BETWEEN

LESLIE NORMAN AUSTIN
Appellant

AND

ROCHE PRODUCTS (NEW ZEALAND) LIMITED
Respondent

Hearing:

 Further submissions:

10 September 2020


24 September 2020

Court:

Glazebrook, O’Regan, Ellen France, Williams and Arnold JJ

Counsel:

G J Thwaite and Y S Kim for Appellant
J A MacGillivray and S M Jass for Respondent
H B Rennie QC and J B Orpin-Dowell for Accident Compensation Corporation as Intervener

Judgment:

31 March 2021

JUDGMENT OF THE COURT

AThe appeal will be dismissed one month from the date of this judgment unless the appellant makes an application under s 135 of the Accident Compensation Act 2001 together with an application to this Court for a stay of this proceeding pending completion of that process.

BThere is no order as to costs.

____________________________________________________________________

REASONS
(Given by Williams J)

Introduction

  1. A person who suffers a “treatment injury” has cover under the Accident Compensation Act 2001.  A treatment injury is an injury that is not an “ordinary consequence” of treatment.  Three issues arose in this appeal: what is treatment; what is an ordinary consequence of treatment; and who has the jurisdiction to decide those questions?

Background

  1. The background to this case is unusual.  The appellant, Mr Austin, suffers from excessive bone growth in his spine.  It causes him pain and stiffness in his neck and back.  Mr Austin claims that these health problems were caused by the prescription drug, Roaccutane,[1] which he took at various times between 1984 (when he was 32) and 2005 at the latest.

    [1]Roaccutane is the brand name for isotretinoin.

  2. In March 2015, by which time he was 63 years old, Mr Austin claimed cover under the Accident Compensation Act (the AC Act) for his condition, which clinicians described as diffuse idiopathic skeletal hyperostosis (DISH), secondary to Roaccutane use.  The Accident Compensation Corporation (ACC) accepted Mr Austin’s claim in December 2015.  In addition to covering his surgery, physiotherapy and consultation costs, ACC paid Mr Austin weekly compensation (including back payments) covering a period of about two years from April 2014.  Mr Austin accepted the clinical treatment and the compensation.  He did not pursue any of the review options under the AC Act to challenge ACC’s acceptance of his claim.  That was unsurprising, because he had succeeded in obtaining the entitlements he claimed.

  3. In 2016, Mr Austin changed his position on his ACC cover.  He commenced proceedings in the High Court against the respondent, Roche Products (New Zealand) Ltd (Roche NZ).  Roche NZ is the New Zealand distributor of Roaccutane.  Mr Austin claimed that Roche NZ had negligently provided him with Roaccutane for which he sought compensatory and exemplary damages.  He says Roche NZ breached a duty of care it owed to him in that it failed to disclose the risks associated with Roaccutane, failed to communicate recommendations about its use, and failed to arrange for the cessation of…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Austin v Roche Products (New Zealand) Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2021] NZSC 30
Decision Date

CaseChat Overview and Summary

The case of Austin v Roche Products (New Zealand) Ltd involved a dispute between Mr Leslie Norman Austin and Roche Products (New Zealand) Ltd, the New Zealand distributor of the prescription drug Roaccutane. Mr Austin claimed that his excessive bone growth in his spine, resulting in pain and stiffness, was caused by the use of Roaccutane. He had previously received compensation from the Accident Compensation Corporation (ACC) for his condition. However, he later sought to sue Roche NZ for allegedly negligently providing him with Roaccutane without disclosing its risks. The primary legal issue was whether Mr Austin's prior claim to coverage under the Accident Compensation Act 2001 prevented him from bringing these proceedings against Roche NZ.

The Supreme Court of New Zealand addressed three main issues: (a) whether Mr Austin’s prior claim to coverage prevented him from bringing these proceedings; (b) if Roche NZ’s failure to obtain Mr Austin’s prior informed consent meant he received treatment when he took Roaccutane; and (c) whether the condition in question was an ordinary consequence of Roaccutane treatment. The Court concluded that section 133(5) of the Act applied, barring Mr Austin from bringing his claim in court. This section prohibits any court from considering or granting remedies in relation to a matter covered by the Act if a person has a claim under the Act and has a right of review or appeal in relation to that claim. The Court found that Mr Austin’s challenge could have been addressed within the Act's procedures, and therefore, his proceedings against Roche NZ were barred.

In light of the decision, the appeal was dismissed and the proceeding would be struck out unless Mr Austin applied for a review under section 135 of the Act within one month of the judgment. The Court did not order costs as Roche NZ had not raised the issue of costs in its submissions.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established